'It's Incredible' Says Mike Tyson As His Medical Marijuana Products Reach Patients In Germany

Zinger Key Points
  • Carma HoldCo further expands its European presence with the launch of Tyson 2.0 medical cannabis products in Germany.
  • To make this launch possible, Carma, partnered with the multinational pharmaceutical company PHCANN.
  • ‘This launch in Germany is a significant achievement in our mission to reach more consumers globally,’ Tyson said.

Medical marijuana products from legendary boxing champion Mike Tyson's brand Tyson 2.0 are now available to patients in Germany, Benzinga exclusively learned.

Carma HoldCo, a global licensing company behind the nation's popular celebrity cannabis and lifestyle brands, previously announced a partnership with the multinational pharmaceutical company PHCANN to exclusively cultivate, manufacture and distribute Tyson 2.0 branded THC products across Germany and the UK. Thanks to this exclusive partnership, Tyson 2.0 medical cannabis products have already reached Europe.

"It's incredible to see TYSON 2.0 expanding across Europe," Tyson, co-founder and chief brand officer, stated.

"Our goal has always been to provide the best cannabis products to those who need them most. This launch in Germany is a significant achievement in our mission to reach more consumers globally."

The Launch

Initially, three strains marketed for their therapeutic advantages – Haymaker Haze, NYC Diesel, and Tiger Milk – will be supplied to pharmacies by Nimbus Health. Patients can now conveniently obtain prescriptions and access these premium products from their homes via telemedicine platforms and online pharmacies.

Adam Wilks,  co-founder and CEO of Carma, said, “The launch of TYSON 2.0 in Germany marks a pivotal milestone in our European market strategy. As the parent company of TYSON 2.0, Carma is committed to broadening its global reach through strategic partnerships and delivering exceptional products. This move aligns with our mission to lead the market and reinforces our commitment to providing top-tier medical cannabis to patients in need.”

Wilks previously discussed Germany's cannabis legalization with Benzinga, announcing a possible expansion in the European nation. "For our company, this reform means an opportunity to further solidify our presence in Europe after TYSON 2.0’s opening of a new branded coffee shop in Amsterdam last year, and capitalize on the emerging cannabis industry in Germany. We’ll be exploring several avenues to enter this market strategically, leveraging our expertise and resources to establish a strong foothold," Wilks said.

To kick off the launch, Tyson2.0 will be presented at the Mary Jane Berlin Cannabis Expo & Chill Festival from June 14 to June 16, one of Europe's largest cannabis trade events. PHCANN's booth at the event will also highlight TYSON 2.0’s brand partners, including Futorola, GrencoScience and Royal Queen Seeds, demonstrating a comprehensive approach to excellence in the cannabis industry.

Speaking of important industry events, don't miss the opportunity to join the Benzinga Cannabis Market Spotlight in New Jersey on June 17th! Grow your business, raise money and capitalize on the booming NJ recreational market. Don't miss this must-attend event in New Brunswick. Secure your tickets now. Very few spots are left. Use the code “JAVIER20” for 20% off

Courtesy Photo

Market News and Data brought to you by Benzinga APIs
Posted In: CannabisNewsExclusivesAdam WilksCarma HoldCoGermany CannabisMIke TysonPHCANNTyson 2.0Tyson 2.0 Germany
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Cannabis rescheduling seems to be right around the corner

Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.